文献速递心力衰竭与心肌病血脂与心血管预防

心力衰竭患者血浆ACE2浓度性别差异及RAAS抑制剂影响

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
PubMed 文献 · Eur Heart J · 2020-01-01

在1485例男性与537例女性心衰患者(索引队列)及1123例男性与575例女性(验证队列)中,男性是血浆ACE2升高的最强预测因素;索引队列中ACEI、ARB或MRA均非独立预测因素,验证队列中ACEI与ARB预测较低ACE2,MRA预测较高ACE2。

要点

  • 男性心衰患者血浆ACE2浓度高于女性。
  • ACEI或ARB使用不增加血浆ACE2浓度。
  • MRA使用在验证队列中与较高ACE2相关。

核心结论

  • 在两个独立心衰队列中,男性血浆ACE2浓度高于女性,但ACEI或ARB使用均未与更高血浆ACE2浓度相关。

研究设计与样本

  • 索引队列纳入1485例男性与537例女性心衰患者,验证队列纳入1123例男性与575例女性心衰患者。
  • 测量血浆ACE2浓度并分析预测因素,中位年龄男性69岁、女性75岁。

主要发现

  • 两个队列中男性性别均为ACE2升高的最强预测因素(索引队列估计值0.26,P<0.001;验证队列估计值0.19,P<0.001)。
  • 索引队列中ACEI、ARB或MRA使用均非血浆ACE2的独立预测因素。
  • 验证队列中ACEI使用(估计值-0.17,P=0.002)与ARB使用(估计值-0.15,P=0.03)为较低血浆ACE2的独立预测因素。
  • 验证队列中MRA使用(估计值0.11,P=0.04)为较高血浆ACE2浓度的独立预测因素。

临床怎么用

  • 心衰患者使用ACEI或ARB不应因担忧升高血浆ACE2而停药。
  • 男性心衰患者血浆ACE2较高或可部分解释COVID-19男性发病率与病死率更高。

局限性

  • 研究仅针对心衰患者,结论外推至其他人群需谨慎。
  • 两个队列中RAAS抑制剂与ACE2的关联结果不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The current pandemic coronavirus SARS-CoV-2 infects a wide age group but predominantly elderly individuals, especially men and those with cardiovascular disease. Recent reports suggest an association with use of renin-angiotensin-aldosterone system (RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability to SARS-CoV-2 in patients on RAAS inhibitors. METHODS AND RESULTS: We measured ACE2 concentrations in 1485 men and 537 women with heart failure (index cohort). Results were validated in 1123 men and 575 women (validation cohort).The median age was 69 years for men and 75 years for women. The strongest predictor of elevated concentrations of ACE2 in both cohorts was male sex (estimate = 0.26, P < 0.001; and 0.19, P < 0.001, respectively). In the index cohort, use of ACE inhibitors, angiotensin receptor blockers (ARBs), or mineralocorticoid receptor antagonists (MRAs) was not an independent predictor of plasma ACE2. In the validation cohort, ACE inhibitor (estimate = -0.17, P = 0.002) and ARB use (estimate = -0.15, P = 0.03) were independent predictors of lower plasma ACE2, while use of an MRA (estimate = 0.11, P = 0.04) was an independent predictor of higher plasma ACE2 concentrations. CONCLUSION: In two independent cohorts of patients with heart failure, plasma concentrations of ACE2 were higher in men than in women, but use of neither an ACE inhibitor nor an ARB was associated with higher plasma ACE2 concentrations. These data might explain the higher incidence and fatality rate of COVID-19 in men, but do not support previous reports suggesting that ACE inhibitors or ARBs increase the vulnerability for COVID-19 through increased plasma ACE2 concentrations.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020. PMID: 32388565. doi:10.1093/eurheartj/ehaa373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。